.png){kind=icon}
.png){kind=icon}
Return
Multiple Myeloma, Version 2.2024
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2023.0061.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combina-tions with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base de-cisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommenda-tions from NCCN Guidelines for MM specific to relapsed/refractory disease.
Keywords:
LENALIDOMIDE PLUS DEXAMETHASONE
HIGH-DOSE CYCLOPHOSPHAMIDE
OPEN-LABEL
ZOLEDRONIC ACID
DARATUMUMAB MONOTHERAPY
SKELETAL EVENTS
ORAL IXAZOMIB
FOLLOW-UP
BORTEZOMIB
CARFILZOMIB
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations